NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free IRWD Stock Alerts $8.12 -0.18 (-2.17%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$8.10▼$8.4550-Day Range$7.60▼$15.1852-Week Range$7.53▼$15.70Volume1.86 million shsAverage Volume4.25 million shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice Target$19.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ironwood Pharmaceuticals alerts: Email Address Ironwood Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside143.8% Upside$19.80 Price TargetShort InterestBearish13.96% of Float Sold ShortDividend StrengthN/ASustainability-2.94Upright™ Environmental ScoreNews Sentiment0.44Based on 10 Articles This WeekInsider TradingSelling Shares$4.16 M Sold Last QuarterProj. Earnings Growth19.72%From $0.71 to $0.85 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.30 out of 5 starsMedical Sector751st out of 5,430 stocksPharmaceutical Preparations Industry235th out of 2,526 stocks 3.5 Analyst's Opinion Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIronwood Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.96% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 3.60%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIronwood Pharmaceuticals has received a 39.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Linaclotide" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ironwood Pharmaceuticals is -2.94. Previous Next 1.9 News and Social Media Coverage News SentimentIronwood Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ironwood Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have sold 2,493.59% more of their company's stock than they have bought. Specifically, they have bought $160,420.00 in company stock and sold $4,160,642.00 in company stock.Percentage Held by Insiders13.10% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to grow by 19.72% in the coming year, from $0.71 to $0.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Read More IRWD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRWD Stock News HeadlinesMay 3, 2024 | americanbankingnews.comIronwood Pharmaceuticals, Inc. to Post Q1 2024 Earnings of $0.14 Per Share, Capital One Financial Forecasts (NASDAQ:IRWD)May 2, 2024 | americanbankingnews.comIronwood Pharmaceuticals (IRWD) Scheduled to Post Quarterly Earnings on ThursdayMay 4, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.May 1, 2024 | businesswire.comIronwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024April 30, 2024 | investorplace.comStock Market Crash Warning: Don't Get Caught Holding These 3 Biotech StocksApril 26, 2024 | americanbankingnews.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of "Buy" from BrokeragesApril 25, 2024 | businesswire.comIronwood Pharmaceuticals to Host First Quarter 2024 Investor Update CallApril 22, 2024 | insidermonkey.com5 Best Low Price Pharma Stocks To Invest InMay 4, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 20, 2024 | nasdaq.comGuru Fundamental Report for IRWDApril 1, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Ironwood Pharma (IRWD)March 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)March 28, 2024 | businesswire.comIronwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)March 20, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - IRWDMarch 16, 2024 | msn.comIronwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock PlungeMarch 13, 2024 | finance.yahoo.comIt’s Time! 3 Failing Biotech Stocks to Sell Right NowMarch 5, 2024 | investorplace.comIt's Time! 3 Failing Biotech Stocks to Sell Right NowMarch 3, 2024 | finance.yahoo.comIRWD Mar 2024 5.000 putMarch 1, 2024 | msn.comIronwood plunges nearly 40% after SBS trial misses secondary goalsMarch 1, 2024 | reuters.comIronwood's bowel disease drug meets main goal of late-stage studyFebruary 29, 2024 | markets.businessinsider.comIronwood Pharmaceuticals: Strong Buy Rating on LINZESS Performance and Apraglutide Market PotentialFebruary 29, 2024 | finance.yahoo.comIronwood Pharmaceuticals Ran Up 32% Over Two Months — And Just Lost It AllFebruary 29, 2024 | reuters.comIronwood says bowel disease treatment meets main goal in late-stage trialFebruary 29, 2024 | markets.businessinsider.comIronwood Pharma: Apraglutide Trial Meets Primary Goal, But Some Secondary Goals Not Met; Stock DipsFebruary 29, 2024 | msn.comWhy Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today?February 29, 2024 | finance.yahoo.comIronwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)February 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), AMN Healthcare Services (AMN) and Ironwood Pharma (IRWD)See More Headlines Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today5/03/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees267Year FoundedN/APrice Target and Rating Average Stock Price Target$19.80 High Stock Price Target$22.00 Low Stock Price Target$14.00 Potential Upside/Downside+143.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($6.51) Trailing P/E RatioN/A Forward P/E Ratio11.44 P/E GrowthN/ANet Income$-1,002,240,000.00 Net Margins-226.37% Pretax Margin-214.14% Return on Equity-185.45% Return on Assets21.00% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual Sales$442.73 million Price / Sales2.87 Cash FlowN/A Price / Cash FlowN/A Book Value($2.21) per share Price / Book-3.67Miscellaneous Outstanding Shares156,530,000Free Float136,024,000Market Cap$1.27 billion OptionableOptionable Beta0.57 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Thomas A. McCourt (Age 67)CEO & Director Comp: $1.61MMr. Sravan Kumar Emany (Age 46)Senior VP, Principal Financial Officer & CFO Comp: $913.88kMr. John Minardo (Age 48)Senior VP, Chief Legal Officer & Secretary Comp: $814.41kDr. Michael Shetzline M.D. (Age 65)Ph.D., Chief Medical Officer, Senior VP and Head of Research & Drug Development Comp: $860.45kMr. Andrew Davis (Age 37)Senior VP & Chief Business Officer Comp: $824.36kMr. Ronald Silver (Age 41)Corporate Controller & Principal Accounting Officer Mr. Marcel MoulaisonVice President of Technical OperationsGreg MartiniVice President of Strategic Finance & Investor RelationsMs. Beth CalitriHead of Corporate Communications & Media RelationsMr. Mike NanfitoVice President of Sales & Sales ExcellenceMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDMannKindNASDAQ:MNKDDynavax TechnologiesNASDAQ:DVAXOPKO HealthNASDAQ:OPKCryoportNASDAQ:CYRXView All CompetitorsInsiders & InstitutionsGSA Capital Partners LLPBought 176,172 shares on 5/3/2024Ownership: 0.113%Daiwa Securities Group Inc.Bought 48,397 shares on 5/2/2024Ownership: 0.032%Tokio Marine Asset Management Co. Ltd.Bought 6,000 shares on 5/2/2024Ownership: 0.012%Mirae Asset Global Investments Co. Ltd.Bought 4,522 shares on 5/1/2024Ownership: 0.060%Principal Financial Group Inc.Bought 3,120 shares on 4/29/2024Ownership: 0.514%View All Insider TransactionsView All Institutional Transactions IRWD Stock Analysis - Frequently Asked Questions Should I buy or sell Ironwood Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRWD shares. View IRWD analyst ratings or view top-rated stocks. What is Ironwood Pharmaceuticals' stock price target for 2024? 5 brokerages have issued 12 month target prices for Ironwood Pharmaceuticals' shares. Their IRWD share price targets range from $14.00 to $22.00. On average, they predict the company's stock price to reach $19.80 in the next year. This suggests a possible upside of 143.8% from the stock's current price. View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts. How have IRWD shares performed in 2024? Ironwood Pharmaceuticals' stock was trading at $11.44 at the beginning of 2024. Since then, IRWD stock has decreased by 29.0% and is now trading at $8.12. View the best growth stocks for 2024 here. Are investors shorting Ironwood Pharmaceuticals? Ironwood Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 21,950,000 shares, an increase of 16.9% from the March 15th total of 18,770,000 shares. Based on an average trading volume of 4,770,000 shares, the short-interest ratio is presently 4.6 days. Approximately 14.5% of the shares of the stock are short sold. View Ironwood Pharmaceuticals' Short Interest. When is Ironwood Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IRWD earnings forecast. How can I listen to Ironwood Pharmaceuticals' earnings call? Ironwood Pharmaceuticals will be holding an earnings conference call on Thursday, May 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 609-800-9909 with passcode "3416473". How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its earnings results on Thursday, November, 9th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.17 by $0.05. The biotechnology company had revenue of $113.74 million for the quarter, compared to analyst estimates of $112.90 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 185.45% and a negative net margin of 226.37%. The company's revenue for the quarter was up 4.7% on a year-over-year basis. During the same period last year, the business earned $0.28 earnings per share. What ETFs hold Ironwood Pharmaceuticals' stock? ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Biotech ETF (XBI) and ALPS Medical Breakthroughs ETF (SBIO).Hartford Multifactor Small Cap ETF (ROSC). What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings? Ironwood Pharmaceuticals updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $435.0 million-$455.0 million, compared to the consensus revenue estimate of $462.8 million. What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO? 7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX). Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Hodges Capital Management Inc. (0.55%), Principal Financial Group Inc. (0.51%), GSA Capital Partners LLP (0.11%), Mirae Asset Global Investments Co. Ltd. (0.06%), Los Angeles Capital Management LLC (0.05%) and Allspring Global Investments Holdings LLC (0.05%). Insiders that own company stock include Andrew Davis, Jason Rickard, Jon R Duane, Julie Mchugh, Mark G Currie, Marla L Kessler, Michael Shetzline, Minardo John, Ronald Silver, Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IRWD) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
